Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Faron Updates on Bexmarilimab Development Program

Faron Pharmaceuticals Ltd (“Faron” or the “Company”) Faron Provides Update on Bexmarilimab Development Program Ahead of R&D Day  · Updated landmark analysis estimates nine-month overall survival rates were 70% for heavily pre-treated, late-stage cancer patients who benefited from treatment with bexmarilimab and 26% for patients who did not benefit from treatment · Biomarker analysis showed widely available blood tests can identity which patients are likely to receive clinical benefit from treatment with bexmarilimab · Treatment with bexmarilimab continues to be well

Castellum divests portfolio in Gävle for SEK 2.3 billion

Castellum is divesting 12 properties in Gävle to Fastighets AB Regio. The sale price is approximately SEK 2.3 billion less overheads and deferred tax totalling approximately MSEK 130. The sale resulted in an impairment of goodwill of approximately MSEK 150 and deferred tax income of approximately MSEK 300. The underlying property value exceeds the latest valuation by approximately 10%.The properties have approximately 107,000 square metres of lettable area and a rental value of MSEK 160 per year. 85% of the tenants are state agencies and include the Swedish Police Authority (

Genova Property Group Year-end Report January–December 2021

Full-year 2021 · Rental income amounted to SEK 319.9m (231.1), an increase of 38%. · Net operating income amounted to SEK 235.3m (177.4), an increase of 33%. · Income from property management increased 63% to SEK 99.2m (60.8), of which income from property management attributable to ordinary shareholders was SEK 39.2m (18.8), corresponding to SEK 0.98 (0.53) per ordinary share. · Net income after tax amounted to SEK 611.0m (418.0), corresponding to SEK 13.66 (10.69) per ordinary share. · Long-term net asset value attributable to ordinary shareholders increased 38% to SEK 3,

Year-end report 2021: Strong growth, positive EBITDA, and a clear plan for increased profitability

Fourth quarter: October-December 2021 · Net sales amounted to MSEK 519.1 (207.0), which corresponds to an increase of 151% (391) compared to the corresponding period previous year. Organic growth amounted to 25% (88). Adjusted for sales of non-recurring pandemic-related hygiene products the previous year, the quarter’s organic growth was 30%. · Adjusted EBITDA* amounted to MSEK 24.1 (45.9), which corresponded to a margin of 4.6% (22.2). · EBITDA amounted to MSEK 13.0 (43.6), corresponding to a margin of 2.5% (21.1). · Net profit/loss for the period amounted to MSEK -25.9 (20.4)

I-Tech AB (publ) Year-end report 2021

I-Tech AB (publ) (ticker ITECH) publish the year-end report 2021. Click here on the 23th of February 2021, at 10.30 to follow the webcast  Click here to go directly to I-Tech's Financial Reports Summary of the period ” Strong development of customer base contributes to improved operating result ” ·Net turnover for the fourth quarter amounted to 11 813 (11 188) kSEK, corresponding to an increase in turnover of 6% (-23%). Operating profit/loss amounted to -2 386 (-3 507)

Viaplay becomes exclusive home of new DreamWorks Animation TV series in seven countries

· Viaplay to show new DreamWorks Animation series based on hit franchises such as “Madagascar”, “The Croods” and “How to Train Your Dragon” · Deal includes more than 400 animated, live-action and non-scripted episodes · Exclusive agreement covers the Nordic countries, the Netherlands and Poland Viaplay and NBCUniversal Global Distribution have finalised a multi-year content partnership that makes Viaplay the exclusive streaming home of DreamWorks Animation series in all five Nordic countries (Sweden, Denmark, Norway, Finland, Iceland), the Netherlands and Poland. Starting in spring

Year-end report 2021

A year of strong growth with a 36% increase in net asset valueIn 2021, John Mattson’s income from property management per share increased 14%, adjusted for non-recurring costs for the year. Net asset value per share increased 36%. John Mattson’s goal is for an average annual increase in income from property management per share of at least 10% and NAV growth per share of at least 10%. Property value increased SEK 7.9 billion in 2021 and amounted to SEK 15.9 billion at the end of December. This means that by the end of 2021, we had reached our goal for the Group’s property value to amount

Phargentis achieves positive results in pilot PK study of its new generic version of COPD treatment indacaterol/glycopyrronium plus DPI device

Phargentis announces another important milestone in achieving positive results in the clinical pilot study of ‘Glide’, its new generic version of COPD treatment indacaterol/glycopyrronium plus Dry Powder Inhaler. The clinical study demonstrated good comparability between ‘Glide’ and originator product Ultibro®Breezhaler®. Phargentis will now proceed to the next pivotal phase of development, on schedule. Global sales of Ultibro[®]Breezhaler[®][ ]exceed 500 MUSD a year.Phargentis has entered the clinical development phase for its second generic inhalation product – the COPD therapy containing

Year-end report

January 1 – December 31, 2021The fourth quarter in figures · Net sales amounted to TSEK 3,925 (3,055). · The loss after tax amounted to TSEK 13,852 (9,839). · The loss per share amounted to SEK 0.20 (0.20). · The cash flow from current operations was negative in the amount of TSEK 11,709 (10,290). · The gross margin reached 52.8% (49.4%). · Electrode sales volume increased by 7% and reached 8,024 (7,492) units. Repeat sales of electrodes to existing customers increased by 12%. The full year in figures · Net sales amounted to TSEK 11,727 (9,521). · The loss

Karnov Group reports fourth quarter and full-year results 2021

Delivering on the expansion strategyFINANCIAL HIGHLIGHTS fourth QUARTER · Net sales increased by 17% to SEK 221 m (189), organic growth was 7%. · EBITA amounted to SEK 32 m (48) with EBITA margin of 14.4% (25.2%). Items affecting comparability amounted to SEK 42 m (12). · Adjusted EBITA amounted to SEK 74 m (60) with EBITA margin of 33.3% (31.7%). · Net result amounted to SEK 1 m (16). · Earnings per share after dilution amounted to SEK 0.01 (0.16). · Adjusted operating cash flow amounted to SEK 248 m (192).   FINANCIAL HIGHLIGHTS full year · Net sales increased

InDex Pharmaceuticals Holding AB (publ) year-end report 2021

First patient enrolled in the phase III study CONCLUDE“At the end of November, the first patient was enrolled in the phase III study CONCLUDE and I am proud that we have achieved this important milestone on the way towards market approval,” says Peter Zerhouni, CEO of InDex Pharmaceuticals. Period October – December 2021 · Net sales amounted to SEK 0.0 (0.0) million · Operating loss amounted to SEK –22.7 (–10.1) million · Result after tax amounted to SEK –22.8 (–10.1) million, corresponding to SEK –0.04 per share (–0.04) before and after dilution · Cash flow from operating

Final Results and Accounts

23 February 2022International Personal Finance plcFull-year Financial Report for the period ended 31 December 2021Principal activityInternational Personal Finance plc specialises in providing unsecured consumer credit to 1.7 million customers through the world's largest home credit business and a leading fintech operator, IPF Digital. STRONG REBOUND IN GROWTH AND FULL YEAR PROFITABILITY Key 2021 highlights Ø  Strong financial performance o  Delivered £67.7 million profit before tax, a year on year increase of £108 million o  All business divisions

Vicore takes major step towards a clinical platform company targeting AT2R – new molecule ready for phase 1

· The new AT2R agonist C106, with patent protection to 2041, is ready to enter a phase 1 trial · Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022 · R&D-day on March 10 with more details on Vicore’s research and development pipelineGothenburg, February 23, 2022 - Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing medicines targeting the angiotensin II type 2 receptor (AT2R), today announces advancing its first new chemical entity from the VP03 program to a first in human phase 1 trial. This molecule is

YIT Corporation: Managers’ transactions – Tercero Invest AB

YIT Corporation Managers’ transactions 23 February 2022 at 9:00 a.m.YIT Corporation: Managers’ transactions – Tercero Invest AB YIT Corporation has received the following notification: YIT Oyj – Managers’ Transactions ____________________________________________ Person subject to the notification requirement Name: Tercero Invest AB Position: Closely associated person (X) Legal person (1):Person Discharging Managerial Responsibilities In Issuer Name: Alexander Ehrnrooth Position: Member of the Board Issuer: YIT Oyj LEI: 529900M13GM4VSTE6W80 Notification

Stora Enso accelerates its growth agenda by exploring expansion in production of renewable consumer packaging board

STORA ENSO OYJ INVESTOR NEWS 23 February 2022 at 9:00 EETStora Enso is starting a feasibility study for the possible conversion of an idle paper machine at its Oulu site in Finland for a high-volume consumer board line. On a successful completion of the feasibility study, an investment decision could be made by the end of 2022 with start-up in 2025. Stora Enso’s strategy is to invest in growth to support the strong, continuous demand for sustainable packaging. This is one of the key strategic focus areas in which the Group is building its market share with both existing and new customers.

SBB, Year-end Report 2021: Earnings per A- and B-share SEK 17.35

SAMHÄLLSBYGGNADSBOLAGET I NORDEN AB (PUBL): YEAR IN BRIEF · Rental income was SEK 5,930m (5,121). · The operating surplus was SEK 4,047m (3,479). · Cash flow from operating activities before changes in working capital was SEK 2,415m (2,232). · Profit before tax increased to SEK 29,474m (10,341), of which: · Profit from property management is included in the amount of SEK 5,397m (2,474). The profit from property management includes costs for early repayment of loans and other items affecting comparability of SEK -416m (-93). · Changes in the values of properties are

Norse Atlantic Airways appoints new Chief Financial Officer and Chief Strategy and Investment Officer

As Norse Atlantic Airways prepares for take-off, the Company strengthens its leadership team by appointing Ben Boiling as Chief Financial Officer and James Lightbourn as Chief Strategy and Investment Officer.“Both Ben and James have been instrumental to establishing Norse and preparing the organization for take-off. With operations to commence in the second quarter, we are making these adjustments to position ourselves for the next phase of the company. I am very pleased that Ben will become a part of the leadership team as Chief Financial Officer and that James will step into the new role

This year, the Fazer Experience Visitor Centre awaits its millionth visitor – the renewed exhibition evokes thoughts about the well-being of people and the environment

Fazer is accelerating its transformation to a modern and responsible food experience company, and this development is reflected in the renewed exhibition at the Fazer Experience Visitor Centre. In this multimedia exhibition, the visitors can experience Fazer with all their senses, think about their personal relationship with food, and take a peek at the exciting future of food. This spring, the millionth visitor will enter the Visitor Centre, opened in 2016.The Fazer Experience Visitor Centre is a unique venue in Finland, and the memorable exhibition describes the growth of the Finnish food

Year-end report 2021

“During the fourth quarter of 2021, order intake rose 44 percent and net sales 18 percent. Operating loss amounted to SEK -17 M (-15),” says Johan Löf, CEO of RaySearchFOURTH QUARTER (OCTOBER – DECEMBER 2021) · Order intake SEK 345.0 M (239.1) · Net sales SEK 188.0 M (159.8) · Operating loss SEK -16.8 M (-14.6) · Loss after tax SEK -16.0 M (-14.2) · Loss per share before/after dilution SEK -0.47 (-0.41) · Cash flow SEK -20.7 M (-21.5) · Order backlog SEK 1,362.9 M (1,169.2) at the end of the period TWELVE MONTHS (JANUARY – DECEMBER 2021) · Order intake SEK 807.

Fellow Finance Plc´s Financial Statements Bulletin 2021

FELLOW FINANCE PLC COMPANY ANNOUNCEMENT 23.2.2022 AT 8:30 AM (EET)Financial Statements Bulletin 1.1.–31.12.2021 Financing volumes continued to grow strongly, the result was burdened by non-recurring costs related to the transition to banking operations JANUARY-DECEMBER 2021 IN BRIEF · Revenue decreased by three percent and was 10,7 million euros (11,1). · Operating profit (EBIT) was -0.9 million euros (0,9). · The amount of financing brokered increased by 60 percent from the previous year and totalled EUR 215.0 million (130.7). · On December 22, 2021, the Extraordinary

Synsam Group’s Year-end report 2021

“Continued strong profitability and growth”1 October – 31 December 2021 · Net sales amounted to SEK 1,245 million (1,093), up 14.0 percent · Organic growth totalled 13.8 percent (19.1) · The gross margin increased to 79.2 percent (76.5) · EBITDA rose to SEK 296 million (279) and the EBITDA margin was 23.5 percent (25.1). Adjusted EBITDA rose to SEK 333 million (292) and the adjusted EBITDA margin was 26.5 percent (26.2) · EBITA amounted to SEK 186 million (190) and the EBITA margin was 14.8 percent (17.1). Adjusted EBITA increased to SEK 223 million (203) and the

President and CEO Elisa Markula to leave Oriola

Oriola Corporation Insider information 23 February 2022 at 8:30 a.m. President and CEO Elisa Markula to leave Oriola Oriola Corporation’s President and CEO Elisa Markula has given notice of her resignation from the company. She will leave her position at Oriola at the latest in August 2022. The search for Elisa Markula’s successor starts immediately. “On behalf of the Board of Oriola, I want to thank Elisa for her contribution for the company during her brief tenure during which we have achieved a lot and look forward to working with her until she leaves the company,” says Panu

Photocure ASA: Results for the fourth quarter of 2021

Oslo, Norway, 23 February 2022: Photocure ASA (OSE:PHO) today reported Hexvix[®]/Cysview[®] revenues of NOK 94.2 million in the fourth quarter of 2021 (Q4 2020: NOK 97.7 million). Unit sales in the U.S. and Europe rose 11% and 12%, respectively, while the revenue comparison was impacted by a one-time reversal of an accrual in the prior-year period and foreign exchange. Photocure has a solid pipeline of anticipated Blue Light Cystoscopy (BLC) tower installations in the U.S. and expects placements to accelerate during the second half of 2022.“Photocure showed strong execution and resilience

There are no items matching the current filter
There are no more items matching the current filter
Back to top